Kirill Osipov commented on the recent invalidation of yet another patent of Russian generic producer Nativa

Pharmaceutical Bulletin – one of the largest professional magazines devoted to Russian pharma – published an article on the recent invalidation of yet another patent of Nativa. Nativa is a Russian generic producer, infamous for its involvement in numerous patent infringement cases with the largest originator makers. Nativa’s patent, rendered invalid in the end of January, was for invention claimed to be dependent on the substance patented by Bristol-Myers Squibb and used in the production of Sprycel.

The Head of Legal Department of ARS-Patent Kirill Osipov provided his comments to Pharmaceutical Bulletin on the case and the acute problem of dependent inventions in general.

The full article is available here.

Make an enquiry

Latest News

Mr. Vladimir Rybakov took part in the FICPI Open Forum in Vienna on October 08 – 12, 2019.


In framework of the Forum he served as a chair on the session “Erroneously filed elements and parts of international applications”. As speakers i...

Read more
ARS-Patent writes about new domestic regulations intended to fight evergreening of pharmaceutical patents


Anna Pustogvar, patent expert at ARS-Patent, and Kirill Osipov, the Head of Legal Department of ARS-Patent, have been published in spring Newsletters ...

Read more

View all our News


Meet with us at 2019 AIPLA Annual Meeting


Kirill Osipov, the Head of Legal Department at ARS-Patent, will be attending 2019 AIPLA Annual Meeting on October 24-26 in National Harbor, MD, USA. ...

Read more
Meet ARS-Patent at 4th China Pharma Intellectual Property Summit 2019


Mikhail Khmara, Managing Partner of ARS-Patent and the Head of Patent Department will attend 4th China Pharma IP Summit 2019 (CPIPS 2019) on October 2...

Read more

See all Events

Back top